Heather Tomlinson of The Guardian writes that her country's slow growth in the biotechnology sector is partly the result of U.S. firms reaping most of the financial gains from highly effective drugs for rheumatoid arthritis, such as Remicade, Enbrel and Humira, all developed by British scientists. She says the U.K. biotechnology industry lags behind because, unlike its American counterparts, it fails to make its research findings commercially viable, and many companies are unwilling to take the financial risk necessary to bring new therapies to the market.

Related Summaries